{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:35:23Z","timestamp":1781663723049,"version":"3.54.5"},"reference-count":58,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"unspecified","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["17\/135\/02"],"award-info":[{"award-number":["17\/135\/02"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2020,4,20]]},"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>There is uncertainty about whether cytoreductive surgery (CRS)+hyperthermic intraoperative peritoneal chemotherapy (HIPEC) improves survival and\/or quality of life compared with standard of care (SoC) in people with peritoneal metastases who can withstand major surgery.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Primary objectives<\/jats:title>\n                  <jats:p>To compare the relative benefits and harms of CRS+HIPEC versus SoC in people with peritoneal metastases from colorectal, ovarian or gastric cancers eligible to undergo CRS+HIPEC by a systematic review and individual participant data (IPD) meta-analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Secondary objectives<\/jats:title>\n                  <jats:p>To compare the cost-effectiveness of CRS+HIPEC versus SoC from a National Health Service (NHS) and personal social services perspective using a model-based cost\u2013utility analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>We will perform a systematic review of literature by updating the searches from MEDLINE, Embase, Cochrane library, Science Citation Index as well as trial registers. Two members of our team will independently screen the search results and identify randomised controlled trials comparing CRS+HIPEC versus SoC for inclusion based on full texts for articles shortlisted during screening. We will assess the risk of bias in the trials and obtain data related to baseline prognostic characteristics, details of intervention and control, and outcome data related to overall survival, disease progression, health-related quality of life, treatment related complications and resource utilisation data. Using IPD, we will perform a two-step IPD, that is, calculate the adjusted effect estimate from each included study and then perform a random-effects model meta-analysis. We will perform various subgroup analyses, meta-regression and sensitivity analyses. We will also perform a model-based cost\u2013utility analysis to assess whether CRS+HIPEC is cost-effective in the NHS setting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Ethics and dissemination<\/jats:title>\n                  <jats:p>This project was approved by the UCL Research Ethics Committee (Ethics number: 16023\/001). We aim to present the findings at appropriate international meetings and publish the review, irrespective of the findings, in a peer-reviewed journal.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PROSPERO registration number<\/jats:title>\n                  <jats:p>CRD42019130504.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-039314","type":"journal-article","created":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T05:46:40Z","timestamp":1589348800000},"page":"e039314","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Cytoreductive surgery (CRS) with hyperthermic intraoperative peritoneal chemotherapy (HIPEC) versus standard of care (SoC) in people with peritoneal metastases from colorectal, ovarian or gastric origin: protocol for a systematic review and individual participant data (IPD) meta-analyses of effectiveness and cost-effectiveness"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0313-9134","authenticated-orcid":false,"given":"Kurinchi","family":"Gurusamy","sequence":"first","affiliation":[{"name":"Division of Surgery and Interventional Science, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire L","family":"Vale","sequence":"additional","affiliation":[{"name":"Meta-analysis Group, MRC Clinical Trials Unit at UCL, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Pizzo","sequence":"additional","affiliation":[{"name":"Department of Applied Health Research, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Bhanot","sequence":"additional","affiliation":[{"name":"Division of Surgery and Interventional Science, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian R","family":"Davidson","sequence":"additional","affiliation":[{"name":"Division of Surgery and Interventional Science, University College London, London, UK"},{"name":"Department of HPB Surgery, Royal Free London NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Mould","sequence":"additional","affiliation":[{"name":"Gynaecological Oncology, University College London Hospitals NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muntzer","family":"Mughal","sequence":"additional","affiliation":[{"name":"Surgery, University College London Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Saunders","sequence":"additional","affiliation":[{"name":"Colorectal and Peritoneal Oncology Centre, The Christie NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Aziz","sequence":"additional","affiliation":[{"name":"Colorectal and Peritoneal Oncology Centre, The Christie NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"O'Dwyer","sequence":"additional","affiliation":[{"name":"Colorectal and Peritoneal Oncology Centre, The Christie NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,5,12]]},"reference":[{"key":"2025101812054786000_10.5.e039314.1","unstructured":"International Agency for Research on Cancer (World Health Organization) . Estimated number of incident cases, both sexes, all cancers excluding non-melanoma skin cancer, worldwide in 2012, 2017. Available: https:\/\/gco.iarc.fr\/today\/online-analysis-table?mode=cancer&mode_population=continents&population=900&sex=0&cancer=29&type=0&statistic=0&prevalence=0&color_palette=default"},{"key":"2025101812054786000_10.5.e039314.2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25596"},{"key":"2025101812054786000_10.5.e039314.3","doi-asserted-by":"publisher","DOI":"10.1038\/srep29765"},{"key":"2025101812054786000_10.5.e039314.4","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.8679"},{"key":"2025101812054786000_10.5.e039314.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2013.10.001"},{"key":"2025101812054786000_10.5.e039314.6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.critrevonc.2016.01.017","article-title":"Progress in treatments for colorectal cancer peritoneal metastases during the years 2010-2015. A systematic review","volume":"100","author":"Baratti","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025101812054786000_10.5.e039314.7","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28373"},{"key":"2025101812054786000_10.5.e039314.8","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/DCR.0000000000000412","article-title":"Epidemiology, management, and survival of peritoneal carcinomatosis from colorectal cancer: a population-based study","volume":"58","author":"Quere","year":"2015","journal-title":"Dis Colon Rectum"},{"key":"2025101812054786000_10.5.e039314.9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq762"},{"key":"2025101812054786000_10.5.e039314.10","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.ejca.2014.03.277","article-title":"Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic disease","volume":"50","author":"Hwang","year":"2014","journal-title":"Eur J Cancer"},{"key":"2025101812054786000_10.5.e039314.11","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-4157-9"},{"key":"2025101812054786000_10.5.e039314.12","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-011-1631-5"},{"key":"2025101812054786000_10.5.e039314.13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.187"},{"key":"2025101812054786000_10.5.e039314.14","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ejso.2015.01.018","article-title":"Trends in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of synchronous peritoneal carcinomatosis of colorectal origin in the Netherlands","volume":"41","author":"Razenberg","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"2025101812054786000_10.5.e039314.15","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-008-9966-2"},{"key":"2025101812054786000_10.5.e039314.16","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ejca.2013.09.024","article-title":"Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases","volume":"50","author":"Elias","year":"2014","journal-title":"Eur J Cancer"},{"key":"2025101812054786000_10.5.e039314.17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2017.03.030","article-title":"The 30-year experience-A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer","volume":"79","author":"Desiderio","year":"2017","journal-title":"Eur J Cancer"},{"key":"2025101812054786000_10.5.e039314.18","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1245\/s10434-015-4853-0","article-title":"A temperature of 40 \u00b0C appears to be a critical threshold for potentiating cytotoxic chemotherapy in vitro and in peritoneal carcinomatosis patients undergoing HIPEC","volume":"22 Suppl 3","author":"Schaaf","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"2025101812054786000_10.5.e039314.19","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.ejso.2014.08.477","article-title":"Quality of life after cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: a systematic review","volume":"40","author":"Seretis","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"2025101812054786000_10.5.e039314.20","doi-asserted-by":"crossref","first-page":"55657","DOI":"10.18632\/oncotarget.17497","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of current evidence","volume":"8","author":"Huang","year":"2017","journal-title":"Oncotarget"},{"key":"2025101812054786000_10.5.e039314.21","doi-asserted-by":"crossref","first-page":"525","DOI":"10.5301\/tj.5000623","article-title":"1St evidence-based Italian consensus conference on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis from ovarian cancer","volume":"103","author":"Cavaliere","year":"2017","journal-title":"Tumori"},{"key":"2025101812054786000_10.5.e039314.22","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ejso.2010.03.005","article-title":"Cost analysis of the combined procedure of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)","volume":"36","author":"Baratti","year":"2010","journal-title":"Eur J Surg Oncol"},{"key":"2025101812054786000_10.5.e039314.23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00249.x"},{"key":"2025101812054786000_10.5.e039314.24","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/SLA.0b013e3181c9b53c","article-title":"Evaluation of the cost-effectiveness of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (peritonectomy) at the St George Hospital peritoneal surface malignancy program","volume":"251","author":"Chua","year":"2010","journal-title":"Ann Surg"},{"key":"2025101812054786000_10.5.e039314.25","article-title":"Is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy cost-effective for metastatic colorectal cancer?","volume":"23","author":"Lee","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"2025101812054786000_10.5.e039314.26","unstructured":"Ludwigs K , Breimer ME , Brorson F , et al . Cytoreductive surgery and intraperitoneal chemotherapy (HIPEC or EPIC) in patients with colorectal adenocarcinoma and peritoneal carcinomatosis. (structured Abstract). Health Technology Assessment Database 2013;4."},{"key":"2025101812054786000_10.5.e039314.27","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/jso.24162","article-title":"Evaluation of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a community setting: a cost-utility analysis of a hospital's initial experience and reflections on the health care system","volume":"113","author":"Naffouje","year":"2016","journal-title":"J Surg Oncol"},{"key":"2025101812054786000_10.5.e039314.28","first-page":"776","article-title":"The cost of cytoreductive surgery and perioperative intraperitoneal chemotherapy in the treatment of peritoneal malignancy in one Greek Institute","volume":"17","author":"Tentes","year":"2012","journal-title":"J Buon"},{"key":"2025101812054786000_10.5.e039314.29","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-009-0487-4"},{"key":"2025101812054786000_10.5.e039314.30","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2168.2000.01538.x"},{"key":"2025101812054786000_10.5.e039314.31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1515\/pp-2016-0010","article-title":"Survival outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from gastric cancer: a systematic review","volume":"1","author":"Chia","year":"2016","journal-title":"Pleura Peritoneum"},{"key":"2025101812054786000_10.5.e039314.32","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/jso.23189","article-title":"Summary of current therapeutic options for peritoneal metastases from colorectal cancer","volume":"107","author":"Chua","year":"2013","journal-title":"J Surg Oncol"},{"key":"2025101812054786000_10.5.e039314.33","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/CAD.0000000000000179","article-title":"The role of HIPEC in the treatment of peritoneal carcinomatosis from gastric cancer: between lights and shadows","volume":"26","author":"Di Vita","year":"2015","journal-title":"Anticancer Drugs"},{"key":"2025101812054786000_10.5.e039314.34","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1515\/pp-2016-0027","article-title":"Randomized controlled trials evaluating cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in prevention and therapy of peritoneal metastasis: a systematic review","volume":"1","author":"Eveno","year":"2016","journal-title":"Pleura Peritoneum"},{"key":"2025101812054786000_10.5.e039314.35","first-page":"20562","article-title":"Cytoreductive surgery combined with intraperitoneal chemotherapy in the treatment of colorectal peritoneal metastasis: a meta-analysis","volume":"9","author":"TF","year":"2016","journal-title":"Int J Clin Exp Med"},{"key":"2025101812054786000_10.5.e039314.36","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000664"},{"key":"2025101812054786000_10.5.e039314.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2015.08.172"},{"key":"2025101812054786000_10.5.e039314.38","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.suronc.2016.09.002","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in elderly patients. A systematic literature review","volume":"25","author":"L\u00f3pez-L\u00f3pez","year":"2016","journal-title":"Surg Oncol"},{"key":"2025101812054786000_10.5.e039314.39","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i38.14018"},{"key":"2025101812054786000_10.5.e039314.40","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.suronc.2018.05.006","article-title":"HIPEC in patients with primary advanced ovarian cancer: is there a role? A systematic review of short- and long-term outcomes","volume":"27","author":"Kireeva","year":"2018","journal-title":"Surg Oncol"},{"key":"2025101812054786000_10.5.e039314.41","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/jso.24813","article-title":"Clinical studies in CRS and HIPEC: trials, tribulations, and future directions-A systematic review","volume":"117","author":"Morano","year":"2018","journal-title":"J Surg Oncol"},{"key":"2025101812054786000_10.5.e039314.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2015.06.005"},{"key":"2025101812054786000_10.5.e039314.43","unstructured":"Ubago-P\u00e9rez R , Matas-Hoces A , Beltr\u00e1n-Calvo C , et al . Hyperthermic intraperitoneal chemotherapy. efficacy and safety in the treatment of ovarian cancer peritoneal carcino matosis (structured Abstract). Health Technology Assessment Database 2013;4."},{"key":"2025101812054786000_10.5.e039314.44","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c221"},{"key":"2025101812054786000_10.5.e039314.45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001855"},{"key":"2025101812054786000_10.5.e039314.46","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3181b13ca2"},{"key":"2025101812054786000_10.5.e039314.47","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000133083.54934.ae"},{"key":"2025101812054786000_10.5.e039314.48","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"2025101812054786000_10.5.e039314.49","unstructured":"Higgins J , Green S . Cochrane Handbook for systematic reviews of interventions version 5.1.0, 2011. www.handbook.cochrane.org"},{"key":"2025101812054786000_10.5.e039314.50","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"2025101812054786000_10.5.e039314.51","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"2025101812054786000_10.5.e039314.52","article-title":"Prognostic relevance of the peritoneal surface disease severity score compared to the peritoneal cancer index for colorectal peritoneal carcinomatosis","volume":"2016","author":"Ng","year":"2016","journal-title":"Int J Surg Oncol"},{"key":"2025101812054786000_10.5.e039314.53","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1245\/s10434-014-3798-z","article-title":"The American Society of peritoneal surface malignancies (ASPSM) Multiinstitution evaluation of the peritoneal surface disease severity score (PSDSS) in 1,013 patients with colorectal cancer with peritoneal carcinomatosis","volume":"21","author":"Esquivel","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"2025101812054786000_10.5.e039314.54","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/21.5.837"},{"key":"2025101812054786000_10.5.e039314.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.04.026"},{"key":"2025101812054786000_10.5.e039314.56","unstructured":"National Institute for Health and Care Excellence . Guide to the methods of technology appraisal 2013, 2013. Available: https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/foreword"},{"key":"2025101812054786000_10.5.e039314.57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189631","article-title":"Cost-Effectiveness of laparoscopic versus open distal pancreatectomy for pancreatic cancer","volume":"12","author":"Gurusamy","year":"2017","journal-title":"PLoS One"},{"key":"2025101812054786000_10.5.e039314.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.02.002"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-039314","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T19:05:55Z","timestamp":1760814355000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-039314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":58,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5,12]]},"published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1136\/bmjopen-2020-039314"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-039314","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}